Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

N Brownlow, C Mol, C Hayford, S Ghaem-Maghami… - Leukemia, 2009 - nature.com
N Brownlow, C Mol, C Hayford, S Ghaem-Maghami, NJ Dibb
Leukemia, 2009nature.com
1 Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S
proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268: 533–
539. 2 Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med
2005; 352: 2487–2498. 3 Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ,
de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory …
1 Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268: 533–539. 2 Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498. 3 Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874.
4 Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14: 451–456. 5 Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S et al. Clioquinol, a therapeutic agent for Alzheimer’s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosisinducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 2007; 67: 1636–1644. 6 Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry 2008; 112: 760–769. 7 Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685–1691.
nature.com